StockNews.AI
KLRS
StockNews.AI
88 days

Kalaris to Participate at Stifel Ophthalmology Forum

1. Kalaris Therapeutics will host a Fireside Chat on May 27th. 2. CEO Andrew Oxtoby and CMO Matthew Feinsod will present. 3. They focus on developing TH103 for retinal diseases. 4. TH103 is in Phase 1 trials for neovascular AMD. 5. Future plans include DME and RVO therapies.

3m saved
Insight
Article

FAQ

Why Bullish?

Kalaris is actively progressing in clinical trials, which often signals market interest and potential growth. Historical precedents show that successful trial announcements can elevate stock prices significantly.

How important is it?

The engagement at a specialized forum may attract investors and analysts, influencing short-term stock performance. The focus on advanced therapies also showcases Kalaris' innovative edge.

Why Short Term?

The upcoming Fireside Chat could quickly influence investor sentiment and stock valuation due to increased visibility and potential news. Examples include companies experiencing spikes following investor presentations.

Related Companies

RGENREGNVRTX
May 23, 2025 11:03 ET  | Source: Kalaris Therapeutics, Inc. PALO ALTO, Calif., May 23, 2025 (GLOBE NEWSWIRE) -- Kalaris Therapeutics, Inc. (Nasdaq: KLRS) (“Kalaris”), a clinical-stage biopharmaceutical company dedicated to the development and commercialization of treatments for prevalent retinal diseases, today announced that management will participate at an upcoming Fireside Chat at the Stifel 2025 Virtual Ophthalmology Forum. Details: Type: Fireside ChatSpeakers: Andrew Oxtoby, Chief Executive Officer & Matthew Feinsod, Chief Medical OfficerDate: Tuesday, May 27th, 2025Time: 08:00 am ETLocation: Webcast Following the event, a replay will be hosted on Kalaris Therapeutics’ Investor Relations webpage. About Kalaris Kalaris is a clinical-stage biopharmaceutical company dedicated to the development and commercialization of treatments for prevalent retinal diseases. The company is focused on development of TH103, a novel, differentiated anti-VEGF investigational therapy. Developed by Dr. Napoleone Ferrara, TH103 is a fully humanized, recombinant fusion protein that acts against VEGF as a decoy receptor and has been specifically engineered for potentially improved VEGF inhibition and longer retention in the retina. TH103 is currently being evaluated in an ongoing, Phase 1 clinical trial for the treatment of neovascular Age-related Macular Degeneration (nAMD), with plans to develop TH103 for additional neovascular and exudative diseases of the retina such as Diabetic Macular Edema (DME), and Retinal Vein Occlusion (RVO). Kalaris Therapeutics Investor Contact: Corey Davis, Ph.D. LifeSci Advisors, LLC +1 212 915 2577 cdavis@lifesciadvisors.com ir@kalaristx.com

Related News